AUNA
Auna S.A.
AUNA trails on the overall score without a compensating advantage in the available component scores.
LLY
Eli Lilly and Company
LLY has the edge over AUNA overall, supported by stronger fundamentals and stronger modeled upside.
AUNA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Healthy | |
| Weak |
AUNA's revenue and cash flow are currently healthy, but its profitability and balance sheet are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
AUNA PE Valuation
AUNA has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
AUNA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Growth | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for AUNA, but weaker profitability. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over AUNA on the outlook, with more favorable profitability expectations.
AUNA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.28 | -130% |
| Q1 2026 | -$0.08 | -113% |
| Q4 2025 | $0.03 | -93% |
| Q3 2025 | $0.74 | +$1.75 |
| Q2 2025 | $0.94 | +$2.61 |
| Q1 2025 | $0.63 | +$2.31 |
| Q4 2024 | $0.41 | +$2.03 |
| Q3 2024 | -$1.01 | -$0.30 |
AUNA has swung to a loss: it lost $0.28 per share over the past year, after a profit the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over AUNA on earnings quality, reporting a profit while its opponent remains loss making.
AUNA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $360.3M | +12% |
| Q1 2026 | $345.3M | +13% |
| Q4 2025 | $331.4M | +6.3% |
| Q3 2025 | $327.8M | -0.8% |
| Q2 2025 | $320.8M | -2.4% |
| Q1 2025 | $305.5M | -3.2% |
| Q4 2024 | $311.7M | +4.1% |
| Q3 2024 | $330.4M | +11% |
AUNA's revenue is growing: $360M last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 12% | -3.7 points |
| Q1 2026 | 13% | -0.8 points |
| Q4 2025 | 13% | -5.9 points |
| Q3 2025 | 15% | -2.9 points |
| Q2 2025 | 16% | -0.2 points |
| Q1 2025 | 14% | -2.9 points |
| Q4 2024 | 19% | +5.9 points |
| Q3 2024 | 18% | +3 points |
AUNA's operating margin was 12% last quarter, down 3.7 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over AUNA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over AUNA on profitability, with a higher operating margin.
AUNA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $35.9M | +9.7% |
| Q1 2026 | $41.3M | +146% |
| Q4 2025 | $20.6M | -56% |
| Q3 2025 | $49.9M | +1.5% |
| Q2 2025 | $32.7M | +29% |
| Q1 2025 | $16.8M | -55% |
| Q4 2024 | $47.1M | +76% |
| Q3 2024 | $49.1M | +50% |
AUNA generated $148M in free cash flow over the past year, up 1.3% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
AUNA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 4.6x | High |
| Q1 2026 | 4.3x | High |
| Q4 2025 | 4.0x | Elevated |
| Q3 2025 | 4.0x | High |
| Q2 2025 | 3.9x | Elevated |
| Q1 2025 | 4.3x | High |
| Q4 2024 | 4.3x | High |
| Q3 2024 | 4.3x | High |
AUNA's net debt is about 4.6 years of its operating earnings (EBITDA), up from 3.9 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over AUNA on leverage, with a lower net debt burden relative to earnings.
AUNA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.3 | Neutral |
| Stochastic | 12.5 | Oversold |
AUNA's weekly RSI is 39 (neutral) and its Stochastic is 13 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
AUNA PE vs Healthcare Sector
| Metric | AUNA | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
AUNA has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
AUNA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.94 | 7.5% below |
| 20 week MA | $5.08 | 10% below |
| 50 week MA | $5.04 | 9.3% below |
| 100 week MA | $5.89 | 22% below |
LLY has stronger trend alignment. AUNA is above 0 of 4 weekly averages versus LLY above 5 of 5.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
AUNA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $9.60 | $6.85 | -29% |
| 2025 | $6.85 | $4.60 | -33% |
| 2026 YTD | $4.60 | $4.57 | -0.7% |
AUNA has finished every year since 2024 lower, and it's down 0.7% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over AUNA on returns for 2026, with the stronger performance.